AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
The company operates through two segments, Finished Pharmaceutical Products and API.
It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures.
In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block.
Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API.
It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices.
The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Country | United States |
IPO Date | Jun 25, 2014 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 1,761 |
CEO | Dr. Yongfeng Zhang Ph.D. |
Contact Details
Address: 11570 6th Street Rancho Cucamonga, California United States | |
Website | https://www.amphastar.com |
Stock Details
Ticker Symbol | AMPH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001297184 |
CUSIP Number | 03209R103 |
ISIN Number | US03209R1032 |
Employer ID | 33-0702205 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yongfeng Zhang Ph.D. | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director |
Dr. Ziping Luo Ph.D. | Chairman of the Board, Chief Scientist & Chief Operating Officer |
William J. Peters M.B.A. | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director |
Dan Dischner M.B.A. | Senior Vice President of Human Resources & Corporate Communication |
Jacob Liawatidewi M.B.A. | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director |
Rong Zhou M.S. | Senior EVice President of Production & EVP of Scientific Affairs |
Tony Marrs M.B.A., M.P.H., M.S. | Executive Vice President of Regulatory Affairs & Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 16, 2024 | 4 | Filing |
Dec 11, 2024 | 4 | Filing |
Nov 13, 2024 | 4 | Filing |
Nov 13, 2024 | 4 | Filing |
Nov 12, 2024 | 4 | Filing |
Nov 08, 2024 | 4 | Filing |
Nov 08, 2024 | 4 | Filing |
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 06, 2024 | 8-K | Current Report |
Sep 17, 2024 | 4 | Filing |